Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 8/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.39 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4128525 | 0.84 | SMN1; SMN2 (0.53) | FBP1LMNASMN1; SMN2GAAHTT | |
| SCHEMBL14283764 | 0.83 | HTT (0.46) | FBP1HSD17B10SMN1; SMN2GAAHTT | |
| SCHEMBL4138730 | 0.82 | FBP1 (0.44) | FBP1HSD17B10HPGDSMN1; SMN2GAA | |
| SCHEMBL4129371 | 0.81 | FBP1 (0.40) | FBP1HSD17B10SMN1; SMN2GAAHTT | |
| SCHEMBL4135187 | 0.81 | FBP1 (0.40) | FBP1HSD17B10SMN1; SMN2GAAHTT | |
| SCHEMBL4137826 | 0.81 | FBP1 (0.40) | FBP1HSD17B10LMNASMN1; SMN2GAA | |
| SCHEMBL4128898 | 0.81 | FBP1 (0.42) | FBP1GAAHTTALDH1A1 | |
| SCHEMBL4129014 | 0.80 | FBP1 (0.39) | FBP1HSD17B10SMN1; SMN2GAAHTT | |
| SCHEMBL4128422 | 0.79 | HTT (0.41) | FBP1GAAHTT | |
| SCHEMBL4127768 | 0.79 | HTT (0.41) | FBP1GAAHTTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090197836-A1 | Combination of FBPase Inhibitors and Antidiabetic Agents Useful for the Treatment of Diabetes | VAN POELJE PAUL D | 2009-08-06 | — | — | US | disclosed |
| US-20090192121-A1 | NOVEL BISAMIDATE PHOSPHONATE PRODRUGS | JIANG TAO | 2009-07-30 | — | — | US | disclosed |
| US-7563774-B2 | Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes | METABASIS THERAPEUTICS, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-20080015195-A1 | Novel Heteroaromatic Inhibitors of Fructose-1,6-Bisphosphatase | METABASIS THERAPEUTICS, INC. (US) | 2008-01-17 | — | — | US | disclosed |
| US-20080004226-A1 | Combination of FBPase Inhibitors and Insulin Sensitizers for the Treatment of Diabetes | METABASIS THERAPEUTICS, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-7312219-B2 | Heteroaromatic inhibitors of fructose 1,6-bisphosphatase | METABASIS THERAPEUTICS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-20070232571-A1 | Novel Heteroaromatic Inhibitors of Fructose-1,6-Bisphosphatase | METABASIS THERAPEUTICS, INC. (US) | 2007-10-04 | — | — | US | disclosed |
| US-6965033-B2 | Bisamidate phosphonate prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2005-11-15 | — | — | US | disclosed |
| EP-1143955-B1 | A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES | METABASIS THERAPEUTICS INC (US) | 2005-07-27 | — | — | EP | disclosed |
| EP-1552850-A2 | A combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes | Metabasis Therapeutics, Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| EP-1112275-B1 | NOVEL HETEROAROMATIC INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE | METABASIS THERAPEUTICS INC (US) | 2003-07-30 | — | — | EP | disclosed |
| US-20030073728-A1 | Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes | METABASIS THERAPEUTICS, INC. | 2003-04-17 | — | — | US | disclosed |
| US-6489476-B1 | FRUCTOSE-1,6-BISPHOSPHATASE ENZYME INHIBITORS ARE USEFUL IN THE TREATMENT OF DIABETES AND OTHER CONDITIONS ASSOCIATED WITH ELEVATED BLOOD GLUCOSE OR EXCESS GLYCOGEN STORAGE. | METABASIS THERAPEUTICS, INC. | 2002-12-03 | — | — | US | disclosed |
| US-20020173490-A1 | Novel bisamidate phosphonate prodrugs | METABASIS THERAPEUTICS, INC. | 2002-11-21 | — | — | US | disclosed |
| EP-1143955-A3 | A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES | Metabasis Therapeutics Inc. (US) | 2002-08-28 | — | — | EP | disclosed |
| WO-2002003978-A2 | A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES | METABASIS THERAPEUTICS, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
| EP-1143955-A2 | A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES | Metabasis Therapeutics Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| EP-1112275-A1 | NOVEL HETEROAROMATIC INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE | Metabasis Therapeutics, Inc. (US) | 2001-07-04 | — | — | EP | disclosed |
| WO-2000038666-A2 | A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES | METABASIS THERAPEUTICS, INC. (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000014095-A1 | NOVEL HETEROAROMATIC INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE | METABASIS THERAPEUTICS, INC. (US) | 2000-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073728-A1 | Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes | FBP1, ALDOA, G6PC1 | FBP1 1/4885HSD17B10 1276/4885LMNA 4420/4885 |
| US-20080015195-A1 | Novel Heteroaromatic Inhibitors of Fructose-1,6-Bisphosphatase | FBP1, ALDOA, G6PC1 | FBP1 1/4885HSD17B10 497/4885LMNA 4489/4885 |
| US-20020173490-A1 | Novel bisamidate phosphonate prodrugs | FBP1, PFKFB1, G6PC1 | FBP1 1/4885HSD17B10 1802/4885LMNA 3965/4885 |
| US-20090197836-A1 | Combination of FBPase Inhibitors and Antidiabetic Agents Useful for the Treatment of Diabetes | FBP1, ALDOA, G6PC1 | FBP1 1/4885HSD17B10 1276/4885LMNA 4420/4885 |
| US-20090192121-A1 | NOVEL BISAMIDATE PHOSPHONATE PRODRUGS | FBP1, PFKFB1, PFKFB2 | FBP1 1/4885HSD17B10 2074/4885LMNA 3896/4885 |
| US-20070232571-A1 | Novel Heteroaromatic Inhibitors of Fructose-1,6-Bisphosphatase | FBP1, ALDOA, G6PC1 | FBP1 1/4885HSD17B10 497/4885LMNA 4489/4885 |
| US-20080004226-A1 | Combination of FBPase Inhibitors and Insulin Sensitizers for the Treatment of Diabetes | FBP1, G6PC1, IRS1 | FBP1 1/4885HSD17B10 1433/4885LMNA 3824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.